PT - JOURNAL ARTICLE AU - Diane Reckziegel AU - Pascal Tétreault AU - Mariam Ghantous AU - Kenta Wakaizumi AU - Bogdan Petre AU - Lejian Huang AU - Rami Jabakhanji AU - Taha Abdullah AU - Etienne Vachon-Presseau AU - Sara Berger AU - Alexis Baria AU - James W Griffith AU - Marwan N Baliki AU - Thomas J Schnitzer AU - A Vania Apkarian TI - Gender dependent pharmacotherapy for blocking transition to chronic back pain: a proof of concept randomized trial AID - 10.1101/19006627 DP - 2019 Jan 01 TA - medRxiv PG - 19006627 4099 - http://medrxiv.org/content/early/2019/09/13/19006627.short 4100 - http://medrxiv.org/content/early/2019/09/13/19006627.full AB - Preventing transition to chronic back pain (CBP) is an ideal strategy that would rescue patients from years to a lifetime of suffering with pain. Recent studies suggest involvement of sexually-dimorphic dopaminergic-motivational circuits in the transition to chronic pain (tCBP), and hints the combination of carbidopa/levodopa and naproxen (LDP+NPX) may block tCBP. We tested these concepts in early onset BP, who were stratified by risk for tCBP using brain properties. Those identified as low-risk entered a no-treatment arm. The rest were randomized into a double-blind, placebo and naproxen (PLC+NPX) controlled trial of oral LDP+NPX for 12 weeks, and a post-treatment 12-weeks follow-up. 59 participants completed the study. Both treatments resulted in ∼50% pain relief for ∼75%, sustained post-treatment. LDP+NPX was highly effective in females (>80% pain relief), it modified BP personality, and was related to objective brain functional changes. Although performed in a small group of early onset BP, multiple subjective and objective measures consistently suggest that these long-duration treatments persistently, and gender-dependently, block tCBP.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01951105Funding StatementThe study was funded by National Institute of Dental and Craniofacial Research (Blue Print grant number R01DE022746) and in part by National Institute on Drug Abuse (P50 DA044121).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData will be available post publication.